open access
Smooth muscle tumor of uncertain malignant potential (STUMP): a case-based analysis
, 2, 1, 3, 1, 1, 1
Affiliations- Department of Obstetrics and Gynecology, Maternal-Fetal Unit, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Türkiye
- Department of Obstetrics and Gynecology, Health Sciences University Zeynep Kamil Women and Children’s Diseases Training and Research Hospital, İstanbul, Türkiye
- Department of Pathology, Umraniye Training and Research Hospital, Istanbul, Turkey
open access
Abstract
Objectives: The present study aimed to analyze of uterine smooth muscle tumors of uncertain malignant potential (STUMP) and the outcomes of patients with STUMP.
Material and methods: In this retrospective study, the data of patients diagnosed with STUMP in a single tertiary center between January 2005–January 2020 were reviewed. We assessed the demographic variables, treatment outcomes, time until recurrence, disease-free and overall survival of the patients.
Results: Twenty-five patients diagnosed with STUMP were included in the study. The mean age of the patients was 43.2 ± 10.3 years. Thirteen of the 25 patients (52%) were treated by myomectomy, others received diagnoses following hysterectomy. The median follow-up time was 45.2 months. Recurrence was observed in three cases (12%), two of which were followed up without hysterectomy, and the third patient died by peritonitis carcinomatosa 60 months after diagnosis although she received cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) treatment.
Conclusions: This study evaluates the data of patients with STUMP. Our results reveal a STUMP recurrence of 12%, like those previously reported in the literature. Despite the possibility of malignant recurrence, fertility-preserving treatment with close follow-up should be tried, because of the relatively early age at diagnosis.
Abstract
Objectives: The present study aimed to analyze of uterine smooth muscle tumors of uncertain malignant potential (STUMP) and the outcomes of patients with STUMP.
Material and methods: In this retrospective study, the data of patients diagnosed with STUMP in a single tertiary center between January 2005–January 2020 were reviewed. We assessed the demographic variables, treatment outcomes, time until recurrence, disease-free and overall survival of the patients.
Results: Twenty-five patients diagnosed with STUMP were included in the study. The mean age of the patients was 43.2 ± 10.3 years. Thirteen of the 25 patients (52%) were treated by myomectomy, others received diagnoses following hysterectomy. The median follow-up time was 45.2 months. Recurrence was observed in three cases (12%), two of which were followed up without hysterectomy, and the third patient died by peritonitis carcinomatosa 60 months after diagnosis although she received cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) treatment.
Conclusions: This study evaluates the data of patients with STUMP. Our results reveal a STUMP recurrence of 12%, like those previously reported in the literature. Despite the possibility of malignant recurrence, fertility-preserving treatment with close follow-up should be tried, because of the relatively early age at diagnosis.
Keywords
uterus; leiomyoma; smooth muscle tumor; sarcoma
About this articleTitle
Smooth muscle tumor of uncertain malignant potential (STUMP): a case-based analysis
Journal
Issue
Article type
Research paper
Published online
2023-02-08
Page views
398
Article views/downloads
390
DOI
Pubmed
Keywords
uterus
leiomyoma
smooth muscle tumor
sarcoma
Authors
Caglar Helvacioglu
Mustafa Eroğlu
Cem Yalçınkaya
Cumhur Selcuk Topal
Işıl Ada Akgul
Sumeyye Cimenli
İbrahim Kale
References (23)- Yordanov AD, Tantchev L, Vasileva P, et al. Uterine smooth muscle tumours of uncertain malignant potential: single-centre experience and review of the literature. Prz Menopauzalny. 2020; 19(1): 30–34.
- Lange S, Pluchino N, Fehlmann A, et al. Prevalence of undiagnosed uterine leiomyosarcoma in women undergoing hysterectomy or myomectomy for benign indications. Eur J Obstet Gynecol Reprod Biol. 2017; 216: 239–244.
- Yadav G, Rao M, Goyal SB, et al. Risk of incidental genital tract malignancies at the time of myomectomy and hysterectomy for benign conditions. Obstet Gynecol Sci. 2021; 64(2): 209–215.
- Rey Valzacchi GM, Rosas P, Uzal M, et al. Incidence of leiomyosarcoma at surgery for presumed uterine myomas in different age groups. J Minim Invasive Gynecol. 2020; 27(4): 926–929.
- Rubisz P, Ciebiera M, Hirnle L, et al. The usefulness of immunohistochemistry in the differential diagnosis of lesions originating from the myometrium. Int J Mol Sci. 2019; 20(5).
- Ganesan R. Uterine smooth muscle tumour of uncertain malignant potential (STUMP): Where are we now? Case Rep Womens Health. 2020; 26: e00176.
- Karataşlı V, Çakır İ, Ayaz D, et al. Clinicopathologic evaluation of uterine smooth muscle tumors of uncertain malignant potential (STUMP): A single center experience. J Gynecol Obstet Hum Reprod. 2019; 48(8): 637–642.
- Rizzo A, Ricci AD, Saponara M, et al. Recurrent uterine smooth-muscle tumors of uncertain malignant potential (STUMP): state of the art. Anticancer Res. 2020; 40(3): 1229–1238.
- Huo L, Wang D, Wang W, et al. Oncologic and reproductive outcomes of uterine smooth muscle tumor of uncertain malignant potential: a single center retrospective study of 67 cases. Front Oncol. 2020; 10: 647.
- Ip PPC, Tse KaYu, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol. 2010; 17(2): 91–112.
- Bell S, Kempson R, Hendrickson M. Problematic uterine smooth muscle neoplasms. Am J Surg Pathol. 1994; 18(6): 535–558.
- Bacanakgil BH, Deveci M, Karabuk E, et al. Uterine smooth muscle tumor of uncertain malignant potential: clinicopathologic-sonographic characteristics, follow-up and recurrence. World J Oncol. 2017; 8(3): 76–80.
- Ha HIn, Choi MC, Heo JH, et al. A clinicopathologic review and obstetric outcome of uterine smooth muscle tumor of uncertain malignant potential (STUMP) in a single institution. Eur J Obstet Gynecol Reprod Biol. 2018; 228: 1–5.
- Şahin H, Karatas F, Coban G, et al. Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes. J Gynecol Oncol. 2019; 30(4): e54.
- Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008; 27(3): 326–332.
- Guntupalli SR, Ramirez PT, Anderson ML, et al. Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol. 2009; 113(3): 324–326.
- Kotsopoulos IC, Barbetakis N, Asteriou C, et al. Uterine smooth muscle tumor of uncertain malignant potential: A rare cause of multiple pulmonary nodules. Indian J Med Paediatr Oncol. 2012; 33(3): 176–178.
- Shapiro A, Ferenczy A, Turcotte R, et al. Uterine smooth-muscle tumor of uncertain malignant potential metastasizing to the humerus as a high-grade leiomyosarcoma. Gynecol Oncol. 2004; 94(3): 818–820.
- Gadducci A, Zannoni GF. Uterine smooth muscle tumors of unknown malignant potential: A challenging question. Gynecol Oncol. 2019; 154(3): 631–637.
- Olga T, Stavroula Lila K, Kounidas G, et al. Uterine smooth muscle tumour of uncertain malignant potential and in vitro fertilization treatment in an infertile patient. SAGE Open Med Case Rep. 2021; 9: 2050313X211012516.
- Campbell JE, Knudtson JF, Valente PT, et al. Successful pregnancy following myomectomy for uterine smooth muscle tumor of uncertain malignant potential: A case report and review of the literature. Gynecol Oncol Rep. 2016; 15: 1–3.
- O'Neill CJ, McBride HA, Connolly LE, et al. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology. 2007; 50(7): 851–858.
- Cao CD, Rico-Castillo J, De Cotiis D, et al. Digital quantification of ki-67 and PHH3 in the classification of uterine smooth muscle tumors. Int J Gynecol Pathol. 2021; 40(6): 549–555.
